ANZCTR search results

A recent survey of community pharmacies across South Australia (unpublished) concluded that it is difficult for community pharmacies to anticipate which medicines to stock for the treatment of symptoms commonly seen in the terminal phase of a palliative illness. This information ties in with other published qualitative studies As a result, a South Australian Palliative Care Formulary Working Party formed and subsequently developed an End of Life Essential Medicines List. This list of medicines was determined following a review of the 6 most frequently encountered symptoms noted in the terminal phase of a palliative illness - nociceptive pain, agitation, nausea/vomiting, dyspnoea, delirium and noisy breathing. The final list of medications was informed by the Working Party’s experience, the Palliative Care Therapeutic Guidelines and other locally used guidelines. The Working Party settled on these medications based on their efficacy, their usefulness in managing more than one symptom and availability on the Schedule of Pharmaceutical Benefits (PBS): - Morphine 10mg/mL Injection - Haloperidol 5mg/mL Injection - Metoclopramide 10mg/2mL Injection - Hyoscine butylbromide 20mg/mL Injection -Clonazepam 1mg Injection A hub pharmacy will be selected in the Victor Harbor Statistical Local Area (SLA): postcode: 5211 The location of the hub pharmacy will be shared with all other community pharmacies within the SLA to encourage quick access to medicines. The location of the hub pharmacy will not be shared with GPs, Nursing homes or patients and their carers. This is a quality improvement initiative. The aim of this audit is to evaluate the impact of this quality improvement strategy on: -Supporting local community clinicians to provide palliative care for non-complex patients through the standardisation of prescribing; -The viability for community pharmacies to stock medicines from an end of life essential medicines list; and -The impact of having a pharmacy hub in a SLA to support prompt and efficient supply of palliative medicines.

In most labours, the baby is delivered head first, face downwards. When the baby is facing sideways (Occiput Transverse) or upwards (Occiput Posterior), the labour may be more difficult, and assisted deliveries including suction cup, forceps, and caesarean section are more likely. When the mother is fully dilated, it is possible to perform an internal examination and to physically rotate the baby to the downwards (anterior) position, but it is unknown if this procedure reduces the chances of an assisted delivery. We plan to run a study looking at whether performing a procedure to turn the baby will reduce the risk of assisted delivery and caesarean section.

We wish to investigate the effect of two different types of thermal stimuli on the responses (spontaneous pain, flare, allodynia and hyperalgesia) to intradermal capsaicin in healthy male volunteers.

Primaquine is a drug that is used to kill malaria parasites that sleep in the liver. Plasmodium vivax and plasmodium ovale are the scientific names of the malaria species that can sleep in the liver. The species These sleeping forms of malaria can wake up and enter the blood where they will cause another bout of malaria. Primaquine is not widely used because it can cause red cells on the blood to break open if they are short of an enzyme called glucose 6 phosphate dehydrogenase, G6PD for short. With little or no G6PD, the red cell cannot produce certain substances to protect itself when it is under stress from certain drugs like primaquine and also fava beans. G6PD deficiency is common in many parts of the world, especially where there is malaria. There are tests that can be used to see if someone is G6PD deficient but many countries do not use them because of cost and the logistical challenges involved. As a result primaquine is not used because of the risk of causing harm to patinets due to the red cells breaking apart is too high. Our research project will look closely at the risk of effects of red cells breaking apart by giving G6PD deficient patients and seeing what happens. We will monitor the patients very closely and have developed a good safety net to detect any health problems quickly. The results of this research will provide useful information for the Ministries of Health that are trying to control malaria.

The internet is increasingly utilised by people with cancer to obtain information and support. However, to date no randomised controlled study has evaluated the effectiveness of a structured online self-help therapeutic program. Therefore, the present study aims to examine how helpful 'Finding My Way' is, an interactive online 6-week self-help coping program, compared to receiving online information only, in improving distress, coping and quality of life after cancer diagnosis.

In most labours, the baby is delivered head first, face downwards. When the baby is facing sideways (Occiput Transverse) or upwards (Occiput Posterior), the labour may be more difficult, and assisted deliveries including suction cup, forceps, and caesarean section are more likely. When the mother is fully dilated, it is possible to perform an internal examination and to physically rotate the baby to the downwards (anterior) position, but it is unknown if this procedure reduces the chances of an assisted delivery. We plan to run a study looking at whether performing a procedure to turn the baby will reduce the risk of assisted delivery and caesarean section.

This study is designed as an observational study on patients being treated with 2.0mg intravitreal aflibercept for exudative age-related macular degeneration in a tertiary retinal clinic. This study does not direct therapy or recommend any treatment other than that the patients be treated in accordance with the aflibercept local product label. Efficacy of the individualized intravitreal aflibercept will be assessed by the changes in bested corrected visual acuity and macular thickness measured by optical coherence tomography, which are the routine eye examinations for monitoring this type of disease. Timing of actual patients visits is at the discretion of the treating physician. The study will be conducted for 30 months with a 6-month recruitment period and 24-month follow up period.

A health professional will deliver the standardised set of information about CVD medicines that are used to reduce the risk of future CVD events in people who have previously experienced a CVD or are at high risk of such an event in the next five years. They will use an interactive tablet application and a written resource during their sessions with the participants. We hypothesis that this will improve participants knowledge about CVD medications and will build their health literacy practices around CVD medications especially with regard to asking questions about their CVD medicines.

The B-VAX Project proposes to support an accredited nurse immuniser to deliver the HBV vaccine to approximately 150 PWID 'in the field' (Footscray, Frankston and Melbourne Central Business District) by using assertive outreach methods and contingency management (small motivational cash incentives) to maximize vaccination course completion. The study will be designed as a randomised control trial (RCT) that will compare the efficacy of two differing vaccine schedules. PWID who have been serologically confirmed as susceptible to HBV infection will be identified from the Melbourne Injecting Cohort Study (MIX) and approached to participate. Consenting participants have already established good rapport with the field researchers, increasing their likelihood to participate in the study. Consenting participants will be randomly allocated to either of the two arms of the study and be provided with the HBV vaccine adhering to either the standard schedule of vaccine delivery at 0, 1 & 6 months, or an opportunistic accelerated schedule, receiving the vaccine at a minimum of 0, 7 & 21 days, with a booster dose 12 months after the third vaccine at ~21 days depending on their immune response to the first three doses. Participants will also be provided with health promotion and prevention education. Participants will have a blood test after each vaccine dose and 6 weeks after the completion of the vaccine schedule to determine their body's immunological response to the vaccine. A sub- set of participants will be invited to answer questions exploring the enablers and barriers for HBV vaccination in a set of open ended questions. The MIX Study: Monash University Project Number: CF09/1262 - 2009000591 DH HREC Project Reference Number: 83/06

Expedited review. Data were retrospectively collected from stroke patients in neurology ward at Chang Gung Memorial Hospital, Linkou since Jan. 1, 2010 to Dec. 31, 2011. Patients not been registered in SRICHS or not enrolled in the HPSAAT were excluded. Matched control group patients were randomly selected from whom did not receive acupuncture therapy among the SRICHS database by 1 : 4 age-sex-severity matching. Profiles including neurologic deficit, activities of daily living, complications, length of stay, and long-term outcome were recorded and evaluated, as well as timing of acupuncture.